New onset atrial fibrilation and risk faktors in COVID-19

被引:23
|
作者
Kelesoglu, Saban [1 ]
Yilmaz, Yucel [2 ]
Ozkan, Eyup [2 ]
Calapkorur, Bekir [2 ]
Gok, Mustafa [2 ]
Dursun, Zehra Bestepe [3 ]
Kilic, Aysegul Ulu [4 ]
Demirelli, Selami [2 ]
Simsek, Ziya [2 ]
Elcik, Deniz [1 ]
机构
[1] Erciyes Univ, Dept Cardiol, Fac Med, Kayseri, Turkey
[2] Kayseri City Hosp, Dept Cardiol, Kayseri, Turkey
[3] Kayseri City Hosp, Dept Infect Dis, Kayseri, Turkey
[4] Erciyes Univ, Fac Med, Dept Infect Dis, Kayseri, Turkey
关键词
COVID-19; Arrhythmia; Atrial fibrillation; Inflammation; CHA2DS2-VASc score; FIBRILLATION;
D O I
10.1016/j.jelectrocard.2020.12.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: There is limited data concerning the prevalence of arrhythmias, particularly atrial fibrillation (AF), which may develop as a consequence of direct myocardial injury and the inflammatory state existing in COVID-19. Methods: This single-center study included data concerning 658 COVID-19 patients, who were hospitalized in our institute, between April 20th, 2020 and July 30th, 2020. Demographic data, findings of the imaging studies, and laboratory test results were retrieved from the institutional digital database. Results: New onset AF (NOAF) was identified in 33 patients (5%). Patients who developed AF were older (72.42 ? 6.10 vs 53.78 ? 13.80, p < 0.001) and had higher frequencies of hypertension and heart failure compared to patients without NOAF (p < 0.001, for both). The CHA2DS2-VASc score was higher in patients, who developed NOAF, compared to those who did not during hospitalization for COVID-19 (p < 0.001). Subjects, who developed NOAF during hospitalization, had a higher leukocyte count, neutrophil / lymphocyte ratio (NLR), C-reactive protein, erythrocyte sedimentation rate, and procalcitonin levels compared to those without NOAF (p < 0.001 for all comparisons). Diffuse lung infiltration was also more frequent in COVID-19 patients, who developed NOAF, during hospitalization (p = 0.015). Multivariate logistic regression analysis demonstrated that age, CHA2DS2-VASc score, CRP, erythrocyte sedimentation rate, and presence of diffuse lung infiltration on thorax CT were predictive for NOAF. Conclusion: The prevalence of NOAF in hospitalized COVID-19 patients is higher than the general population. Age, CHA2DS2-VASc score, C-reactive protein, erythrocyte sedimentation rate, and presence of diffuse lung infiltration on thorax CT may be used to identify patients at high risk for development of NOAF. Especially among these parameters, the presence of diffuse lung infiltration on thorax CT it was the most powerful independent predictor of NOAF development. ? 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:76 / 81
页数:6
相关论文
共 50 条
  • [31] Incidence of new-onset atrial fibrillation in COVID-19 is associated with increased epicardial adipose tissue
    Slipczuk, Leandro
    Castagna, Francesco
    Schonberger, Alison
    Novogrodsky, Eitan
    Dey, Damini
    Jorde, Ulrich P.
    Levsky, Jeffrey M.
    Di Biase, Luigi
    Garcia, Mario J.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2022, 64 (02) : 383 - 391
  • [32] Does new onset and pre-existing atrial fibrillation predict mortality in COVID-19 patients?
    Selim Aydemir
    Emrah Aksakal
    Faruk Aydınyılmaz
    Oktay Gülcü
    İbrahim Saraç
    Sidar Şiyar Aydın
    Remziye Doğan
    Merve Lazoğlu
    Kamuran Kalkan
    The Egyptian Heart Journal, 74
  • [33] Anticoagulating New-Onset Atrial Fibrillation After COVID-19: A Single-Center Experience
    Babb, Miles
    Stevenson, Kurt
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [34] The Effectiveness of Covid 19 Vaccines Against New Onset Atrial Fibrillation in Hospitalized Covid 19 Patients
    Vargas, Gustavo A.
    Azarbal, Jilla R.
    Tang, Fei
    Hammel, Iriana S.
    CIRCULATION, 2022, 146
  • [35] Atrial fibrillation as a risk factor of severe course of COVID-19
    Mielczarek, A.
    Kasprzak, J. D.
    Plewka, M.
    EUROPEAN HEART JOURNAL, 2021, 42 : 413 - 413
  • [36] COVID-19 VACCINES AND ATRIAL FIBRILLATION RISK: A PHARMACOVIGILANCE ANALYSIS
    Kattubadi, Ayeesha
    Solorzano, Juan
    Feng, Katey
    Brar, Vijaywant
    Dominic, Paari
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1838 - 1838
  • [37] Incidence of COVID-19 and Risk of Diabetic Ketoacidosis in New-Onset Type 1 Diabetes
    Kamrath, Clemens
    Rosenbauer, Joachim
    Eckert, Alexander J.
    Pappa, Angeliki
    Reschke, Felix
    Rohrer, Tilman R.
    Moenkemoeller, Kirsten
    Wurm, Michael
    Hake, Kathrin
    Raile, Klemens
    Holl, Reinhard W.
    PEDIATRICS, 2021, 148 (03)
  • [38] COVID-19: confronting a new world risk
    Wardman, Jamie K.
    Lofstedt, Ragnar
    JOURNAL OF RISK RESEARCH, 2020, 23 (7-8) : 833 - 837
  • [39] COVID-19 and New-Onset Psychosis: A Comprehensive Review
    Moccia, Lorenzo
    Kotzalidis, Georgios D.
    Bartolucci, Giovanni
    Ruggiero, Sara
    Monti, Laura
    Biscosi, Marco
    Terenzi, Beatrice
    Ferrara, Ottavia M.
    Mazza, Marianna
    Di Nicola, Marco
    Janiri, Delfina
    Simonetti, Alessio
    Caroppo, Emanuele
    Janiri, Luigi
    Sani, Gabriele
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (01):
  • [40] New-onset autoimmune disease after COVID-19
    Hileman, Corrilynn O.
    Malakooti, Shahdi K.
    Patil, Nirav
    Singer, Nora G.
    Mccomsey, Grace A.
    FRONTIERS IN IMMUNOLOGY, 2024, 15